Gennova’s biosimilar tenecteplase (Elaxim^®), a third-generation thrombolyte which is a modified version of natural tissue plasminogen activator, is indicated for use in the reduction of mortality associated with acute myocardial infarction (AMI). Elaxim^® was launched in 2007 in three vial presentations (Elaxim^®– 30mg, Elaxim^®– 40mg and Elaxim^®– 52.5mg) for single intravenous (IV) bolus administration. Gennova is credited to have launched the only biosimilar of this product in the world. Gennova succeeded in making the drug highly competitive in the Indian market by launching at nearly one-third the price of the innovator in 2007. Today, Elaxim^® continues to be the market leader in India (as per IMS), a significant scientific and commercial achievement which can be attributed to Gennova’s proprietary innovative manufacturing technologies.